期刊名称：JOURNAL OF UROLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
|
|
Official Journal of the
American Urological Association®
Subscribe Today
Renew Today
Trial Issue |
| NEW ONLINE SERVICES NOW AVAILABLE! |
Recent enhancements to LWW Online have expanded the capabilities of this web site. Subcribers and AUA members - please confirm your current user profile the next time you login and be sure to check out some of the following new features:
Dedicated login information - help to get you activated and logged-in now.
New online services for subscriber and non-subscribers - eAlerting, pay-per-view, and more.
Cross title searching - search across all content in the LWW Online archive at one time.
New login screens and navigation - get to where you want to go fast. | | |
The American Urological Association® and Lippincott Williams & Wilkins are pleased to provide access to online full-text content published in the print version of The Journal of Urology® at this web site available in both HTML and PDF formats. The online archive begins with the January 1998 issue, and new content is posted around the time that the printed journal mails.
JOURNAL DESCRIPTION
The most widely read publication in the field, The Journal of Urology® brings solid coverage - all the clinically relevant information needed to stay at the forefront of this dynamic field. The journal presents investigative studies on critical areas of research and practice; survey articles providing short condensations of the best and most important urology literature worldwide; and practice-oriented reports on interesting clinical observations. | |
|
Instructions to Authors
|
Information for Authors
The Journal of Urology® contains 4 sections: Clinical Urology, Pediatric Urology, Investigative Urology and Urological Survey. Rapid Communications are welcomed.
The Clinical Section usually does not publish laboratory animal studies. The Investigative Section does not publish letters to the editor, case reports or clinically oriented articles, and does not require prior approval for Review Articles. Unsolicited material is not accepted by Urological Survey. |
| |
All manuscripts submitted for publication and communications concerning editorial matters should be sent to:
Dr. Jay Y. Gillenwater
1120 N. Charles Street
Baltimore, Maryland 21201-5559, USA
Telephone (410) 223-4312, FAX (410) 223-4373
e-mail: publications@auanet.org
SUBMISSION LETTER. Manuscripts must be accompanied by a cover letter and AUA® Disclosure Form (see last page) signed by all authors. The letter should contain statements indicating the following: 1) that all authors have made a substantial contribution to the information or material submitted for publication; 2) that all have read and approved the final manuscript; 3) that they have no direct or indirect commercial financial incentive associated with publishing the article; 4) that the source of extra-institutional funding, particularly that provided by commercial sources, is indicated; 5) that the manuscript or portions thereof are not under consideration by another journal or electronic publication and have not been previously published. The number of authors should be limited to 6. If more than that number are listed, the senior author must justify the inclusion of each individual. One of the authors should be designated as correspondent and the complete address, telephone number, FAX number and e-mail address provided. Any deviation from these requirements requires justification. The authors should submit names of reviewers.
The cover letter must also include the following paragraph: ¡°In consideration of the Editors of The Journal of Urology® taking action in reviewing and editing this submission, the author(s) undersigned hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership to the American Urological Association, Inc.®, Copyright Owner of The Journal of Urology®, in the event that such work is published in that Journal. All authors have read and comply with the requirements set forth in Information for Authors.¡±
CONFLICT OF INTEREST/DISCLOSURE POLICY. To comply with current standards for scientific journals, authors submitting manuscripts to The Journal of Urology® are responsible for recognizing and disclosing conflicts relevant to their work.
- Authors must describe all sources of financial support for their research/study, and this information will be published with the article.
- Authors must affirm that no funding agreement limits their ability fairly to complete and publish their research/study, and that they had full control of primary data.
- Authors have read and signed the AUA Disclosure Form.
AUTHOR'S RESPONSIBILITY. The corresponding author is responsible for indicating the source of extra-institutional funding, in particular that provided by commercial sources, internal review board approval of study, accuracy of the references and all statements made in their work, including changes made by the copy editor. Authors are expected to submit complete and correct manuscripts. Due to the large number of high quality articles being submitted and to avoid significant delay in publication, the Editors find it necessary to insist that the length of manuscripts, and number of references and illustrations conform to the requirements indicated herein. No paper will be reviewed until these requirements are met. Page proofs will be mailed to the corresponding author for approval and essential corrections will be made. However, the editorial office reserves the right to disallow extensive alterations. Published manuscripts become the sole property of The Journal of Urology® and copyright will be taken out in the name of the American Urological Association Education and Research, Inc.®
Rapid Review Manuscripts that contain important and timely information will be reviewed by 2 consultants and the editors within 72 hours of receipt, and authors will be notified of the disposition immediately thereafter. If and when accepted these articles will be scheduled in the next available issue. A $250 processing fee should be forwarded with the manuscript at the time of submission. Checks should be made payable to the American Urological Association. If the editors decide that the paper does not warrant rapid review, the fee will be returned to the authors, and they may elect to have the manuscript continue through the standard review process. Payment for rapid review guarantees only an expedited review and not acceptance.
Original Articles should be arranged as follows: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Conclusions, References, Tables, Legends. Pages should be numbered and only 1 side of the page should be used. The title page should contain a concise, descriptive title, the names and affiliations of all authors, and a brief descriptive runninghead not to exceed 80 characters. One to five key words should be typed at the bottom of the title page. These words should be identical to the medical subject headings (MESH) that appear in the Index Medicus of the National Library of Medicine. The abstract should not exceed 250 words and must conform to the following style: Purpose, Materials and Methods, Results and Conclusions.
References should not exceed 20 readily available citations for all original articles (except Review Articles and Case Reports). Self-citations should be kept to a minimum. References should be cited by superscript numbers as they appear in the text, and they should not be alphabetized. References should include the names and initials of the first 6 authors, the complete title, the abbreviated journal name according to the Index Medicus of the National Library of Medicine, the volume, the beginning page number and the year. References to book chapters should include names and initials of the first 6 chapter authors, chapter title, book title and edition, names and initials of the first 6 book editors, city of publisher, publisher, volume number, chapter number, page range and year. In addition to the above, references to electronic publications should include type of medium, availability statement and date of accession.
The statistical methods should be indicated and referenced. Enough information should be presented to allow an independent critical assessment of the data.
Illustrations and tables should be kept to a necessary minimum and their information should not be duplicated in the text. No more than 10 illustrations should accompany the manuscript for clinical articles. Illustrations should be unmounted, not attached by clips and submitted as glossy prints no larger than 5 ¡Á 7 inches. The names of all authors and the top of the illustration should be indicated on the reverse side. Legends should be typed double-spaced on a separate page. Magnifications for photomicrographs should be supplied and graphs should be labeled clearly. Reference to illustrations, numbered with Arabic numerals, must be provided in the text. Blurry or unrecognizable illustrations are not acceptable. Color work or an excessive number of illustrations can be published only at the author's expense of $450 per page. Tables should be typed double-spaced on separate pages, numbered and referred to in the text. In general, they should present summarized rather than individual raw data.
Case Reports should be informative and devoid of irrelevant details, including tabulated material. Length should not exceed 500 words, 2 illustrations and 3 references; no abstract is required.
Urologists at Work is a brief communication of a technique of a practical nature, which should include data documenting the experience with the technique advocated. The format is the same as that of an Original Article.
Letters to the Editor should be useful to urological practitioners. The length should not exceed 500 words. Only Letters concerning articles previously published in the Journal are considered.
Review and State of the Art Articles should not be submitted without prior approval. Queries for these articles should be accompanied by a detailed outline of the proposed article, an abstract not to exceed 750 words and an estimate of the length of the manuscript to be submitted. The format is the same as that of an Original Article.
Video Clips may be submitted for posting on The Journal web site. They are subject to peer review. Video files must be compressed to the smallest possible size that still allows for high resolution and quality presentation. The size of each clip should not exceed 5MB. File size limitation is intended to ensure that end-users are able to download and view files in a reasonable time frame. If files exceed the specified size limitation, they will not be posted to the web site and returned to the author for resubmission. For complete instructions e-mail: publications@auanet.org.
PERSONAL COMPUTER DISKETTES. For articles accepted for publication only, authors are encouraged to submit 3.5-inch computer diskettes of the final version of their manuscripts, along with the typed revised manuscript. Diskettes should be labeled with the title of the article, first listed author, Journal of Urology manuscript number, word processing software version used and the date of the last revision. The electronic copy of the manuscript must be identical to the accepted final version of the hard copy. Diskettes produced on IBM or IBM compatible computers using Microsoft Word or WordPerfect are preferred. However, most diskettes produced with other computers or software can be converted. The Journal of Urology® does not assume responsibility for errors in conversion of new or customized software.
| Anayltical Reporting Checklist for Authors |
Put Page Numbers in Appropriate Column Below |
| Animal Experiment |
Cohort Study |
Randomized Trial |
| 1. Primary Objective or major hypothesis of study |
|
|
|
| 2. Justification of sample size |
|
|
|
| 3. Participation rate if patients declined study |
|
| >
|
| 4. Inclusion/exclusion criteria |
|
|
|
| 5. Source and initial number of patients |
|
|
|
| 6. Randomization method |
|
|
|
| 7. Blinding techniques |
|
|
|
| 8. Accrual dates |
|
|
|
| 9. Identification of transformations or categorization of variables, if done |
|
|
|
| 10. Justification if outliers were omitted from analysis |
|
|
|
| 11. Reasons for and analysis of patients withdrawn or protocol deviations |
|
|
|
| 12. Reporting of time between randomization and start of treatment |
|
|
|
| 13. Number of subjects who completed treatment(s) |
|
|
|
| 14. Treatment of missing values |
|
|
|
| 15. Frequency of side effects |
|
|
|
| 16. Identification of statistical software |
|
|
|
| 17. Justification if 1-tailed statistical tests are used |
|
|
|
| 18. Verification of statistical test assumptions |
|
|
|
| 19. Identification of all statistical tests with description or references |
|
|
|
| 20. Median followup time for censored patients |
|
|
|
| 21. Lost to followup expressed as the proportion of censored patients not evaluated during a specified time |
|
|
|
| 22. Reporting of the number of patients at risk over time |
|
|
|
| 23. Confidence intervals for effect sizes |
|
|
| Recommendations
- All subgroup analyses and covariate inclusions should be motivated prior to the Results section. Hypotheses which were not established prior to initial analyses should be clearly identified.
- Variables should be clearly defined, such as specific assays, references for staging, references for validation of survey instruments, etc.
- Treatment regimens should be described well enough for another study to replicate.
- It should be clear which statistical test is associated with each p value reported.
- Rarely used statistical techniques should be described.
- Medians and percentiles (such as quartiles) are preferred over means and standard deviations (or standard errors) when analyzing asymmetric data, especially when nonparametric statistics are calculated.
- Fractions (e.g., 5/10) should accompany percentages.
- In randomized clinical trials, consider reporting separate analyses with confounding variables included.
- If sample sizes differ between groups when patients are randomized, reasons should be provided.
- Report median survival (using Kaplan-Meier) rather than mean survival if any data are censored.
- Comparing survival functions (e.g., with a log rank test) is more efficient than analyzing particular time estimates (e.g., 5-year survival).
- Use appropriate figures. Scatter plots are useful for illustrating important correlations between variables. If subjects are repeated in a figure (e.g., over time), an individual's set of points should be joined with line segments. Different symbols should be used when points are stacked on top of each other. Illustrations of regression lines should be overlaid on raw data. Regression lines should not extend beyond the range of the predictor variable.
- Confidence intervals are more appropriate than standard errors for comparison of groups.
- Use appropriate tables. Coefficients and standard errors are useful for interpreting regression predictors. One significant figure beyond the level measured is sufficient for means, standard deviations, standard errors, etc. One decimal place for percentages greater than 1% is sufficient; no decimal places if the sample size is less than 100. Two significant figures for test statistics and p values are sufficient. Means should generally be accompanied by some measure of their uncertainty, such as confidence intervals or standard errors.
- Confidence intervals should be reported when possible.
- When a statistical hypothesis test is not rejected, the actual p value (e.g., 0.07) should be reported (if known) rather than omitted or reported as p >0.05.
- Pay close attention to wording. The word ¡°correlation¡± is generally reserved for computing correlation coefficients. The word ¡°association¡± is usually preferred. Statistical tests can be nonparametric; data cannot. Studies with negative findings (i.e., no difference) may be the result of low statistical power (e.g., small sample size), rather than absence of a difference, and this limitation should be made clear. Trends that are not statistically significant should not be identified. A p value is the probability of observing data as extreme as those reported if the null hypothesis of no difference is true. A p value is not the probability of no real effect, nor is it necessarily related to the clinical importance.
Manuscript Checklist
 |
1. Manuscript and illustrations (glossy prints) are in quadruplicate. |
|
2. Typed manuscript is double-spaced with wide margins on 8½ x 11-inch paper and does not exceed 2,500 words for Original
Article or Urologists at Work article, or 500 words for Case Report or Letter to the Editor. |
|
3. Standard abbreviations are defined when first used and are consistent throughout the text. |
|
4. Generic names are used for all drugs. Trade names are avoided. |
|
5. Normal laboratory values are provided in parentheses when first used. |
|
6. Submission letter and disclosure form, signed by all authors, are included. |
|
7. Research or project support/funding is included in an acknowledgment. |
|
8. References are accurate, complete and in numerical order as they appear in the text. |
|
9. A corresponding author and complete address, telephone and FAX numbers, e-mail address and word count are provided. |
|
10. Written permission from publishers to reproduce or adapt a previously published illustrations or tables is included. |
|
11. Informed consent forms for identifiable patient descriptions, photographs and pedigrees are included. |
|
12. Analytical reporting checklist completed. |
|
13. Gender and minorities in collection and analyses of data are identified. |
|
14. Abbreviations for human genes should be written in italicized capital letters; protein products should be written in capital letters and not italicized. |
|
15. Abbreviations for animal genes should be written in italics with only the first letter capitalized; protein products should be written with only the first letter capitalized and not italicized. |
AUA Disclosure Form
Annual Statement for the Year 2003 (January 1, 2003 through December 31, 2003)
Code: JU Author
Background and Intent The American Urological Association, Inc.® must ensure balance, independence, objectivity, and scientific rigor in all its individually or jointly sponsored educational activities. All individuals participating in any AUA sponsored activity are expected to disclose all financial interests and/or other relationships with all manufacturer(s) of product(s) and/or provider(s) of services, including alternative treatment technologies. (Financial interests or other relationships can include such things as grants or research support, employee, consultant, major stockholder, member of Speaker's Bureau, etc.) The intent of this disclosure is not to prevent an individual with a financial or other relationship with provider(s) or manufacturer(s) from participation, but rather to provide the audience and listeners with information regarding such relationships from which the audience and listeners can make a judgment. It remains for the listeners to determine whether the presenters' interests or relationships influence the presentation with regard to exposition or conclusion.
Sanction Failure to follow the disclosure policy will result in the following sanction. If an individual fails to accurately and fully disclose such information as required in the Disclosure Form including legible name and address, then he/she will be disqualified from participation as a Faculty Member, Speaker, Moderator, Committee Member or Author of any AUA sponsored or associated activity/publication for a period of not less than 12 months.
Instructions If the individual who is requested to complete the Disclosure Form believes that no relationship as defined in the ¡°Background and Intent¡± section of this document exists and therefore, no disclosure is necessary, he/she should complete Statement #1.
If the individual who is requested to complete the Disclosure Form perceives that disclosure of information is required as outlined in the ¡°Background and Intent¡± section of this document, then he/she should complete Statement #2.
Mandatory Information
Print Clearly or Type Name, Address, Phone Number, and Fax Number
Last Name First Phone Number Fax Number AUA ID #
Address City State/Country Zipcode
Statement #1 (No Disclosure Necessary)
I have read the AUA's statement on ¡°Disclosure Form¡± (Background and Intent) and am in support of it. To the best of my knowledge, I do not have any existing or potential interest that may be perceived as influencing my service in any AUA sponsored Educational Activities/Publications, or other activities.
Signature Date
Statement #2 (Disclosure Necessary)
I believe I have an interest which may be perceived as influencing my service in AUA sponsored Educational Activities/Publications, or other activities. I am hereby disclosing all relationships and, if appropriate, will agree to be excluded or will disqualify myself from participation in any AUA matter. I have involvement with the for-profit or not-for-profit firms/organizations/companies below:
Signature Date |
 | |
Editorial Board
Editor
Jay Y. Gillenwater
1120 North Charles Street
Baltimore, Maryland 21201
|
Associate Editors
Peter R. Carroll
San Francisco, California |
|
Edward J. McGuire
Ann Arbor, Michigan |
Martin I. Resnick
Cleveland, Ohio |
|
Section Editors
Jack S. Elder
Cleveland, Ohio |
|
Anthony Atala
Boston, Massachusetts |
|
Ralph V. Clayman
Orange, California |
|
Assistant Editors
Steven C. Campbell
Maywood, Illinois
|
|
H. Gil Rushton, Jr.
Washington, D.C. |
|
William D. Steers
Charlottesville, Virginia |
Michael A. O'Donnell
Iowa City, Iowa |
|
Mark P. Schoenberg
Baltimore, Maryland |
|
J. Stuart Wolf, Jr.
Ann Arbor, Michigan |
|
Editorial Board
Mid-Atlantic
Burkhardt H. Zorn
Washington, D. C.
New England
Kevin R. Loughlin
Boston, Massachusetts
|
|
New York
Carl A. Olsson
New York, New York
Northeastern
William C. Hulbert, Jr.
Rochester, New York |
| North Central |
Robert C. Flanigan
Maywood, Illinois
|
|
Drogo K. Montague
Cleveland, Ohio |
| South Central |
H. Barton Grossman
Houston, Texas
|
|
R. Duane Cespedes
San Antonio, Texas |
| Southeastern |
Jerry W. Sullivan
New Orleans, Louisiana
|
|
Joseph A. Smith, Jr.
Nashville, Tennessee |
| Western |
Donald E. Novicki
Scottsdale, Arizona |
|
Brent W. Snow
Salt Lake City, Utah |
|
Specialty Society Editors
Confederacion Americana de Urologia
Arturo Mendoza-Valdes
Mexico
|
|
Society of Endourology
Stephen Y. Nakada
Madison, Wisconsin |
|
Society of Urodynamics and Female Urology
Elizabeth A. Gormley
Lebanon, New Hampshire |
European Association of Urology
Alexandre R. Zlotta
Brussels, Belgium
|
|
Society of Male Reproduction
Craig Niederberger
Chicago, Illinois |
|
Urologic Society for Transplantation and Vascular Surgery
Christian S. Kuhr
Seattle, Washington |
Sexual Medicine Society of North America
John P. Mulhall
New York, New York
|
|
Society for Pediatric Urology
H. Gil Rushton
Washington, D.C. |
|
Urological Association of Asia
Christopher Cheng
Singapore |
Society of Basic Urologic Research
Ralph Buttyan
New York, New York
|
|
Society of Urologic Oncology
Michael S. Cookson
Nashville, Tennessee |
|
|
|
Board of Consultants
Brent Blumenstein
Durham, North Carolina
|
|
Jonathan A. Fletcher
Boston, Massachusetts |
|
Seth P. Lerner
Houston, Texas |
Fred L. Coe
Chicago, Illinois
|
|
Lance K. Heilbrun
Detroit, Michigan |
|
Gregory MacLennan
Cleveland, Ohio |
Michael B. Cohen
Iowa City, Iowa
|
|
Michael W. Kattan
New York, New York |
|
Derek Raghavan
Los Angeles, California |
Fred Dorey
Los Angeles, California
|
|
Erich K. Lang
New Orleans, Louisiana |
|
Arthur T. Rosenfield
New Haven, Connecticut |
Robert Elashoff
Los Angeles, California
|
|
Steven A. Leibel
New York, New York |
|
Deborah S. Smith
New Haven, Connecticut |
|
Former Editors
Hugh H. Young
1917-1945
|
|
J. A. Campbell Colston
1946-1965 |
|
Hugh J. Jewett
1966-1977 |
William W. Scott
1977-1983
|
|
Herbert Brendler
1983-1985 |
|
John T. Grayhack
1985-1994 | |
|
刊名字顺( Alphabetical List of Journals):
返回页首 